Search

Your search keyword '"Migliaccio, Ilenia"' showing total 239 results
Start Over Author "Migliaccio, Ilenia"
239 results on '"Migliaccio, Ilenia"'

1. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, Fu, Xiaoyong, Cataldo, Maria Letizia, Nardone, Agostina, Pereira, Resel, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Sethunath, Vidyalakshmi, Wang, Tao, Hilsenbeck, Susan G, Benelli, Matteo, Migliaccio, Ilenia, Guarducci, Cristina, Malorni, Luca, Litchfield, Lacey M, Liu, Jiangang, Donaldson, Joshua, Selenica, Pier, Brown, David N, Weigelt, Britta, Reis-Filho, Jorge S, Park, Ben H, Hurvitz, Sara A, Slamon, Dennis J, Rimawi, Mothaffar F, Jansen, Valerie M, Jeselsohn, Rinath, Osborne, C Kent, and Schiff, Rachel

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Breast Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Antineoplastic Agents, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Female, Humans, Piperazines, Pyridines, Receptors, Estrogen, Signal Transduction, Tumor Cells, Cultured, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeCyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER+)/HER2- breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of sensitivity and resistance to CDK4/6i may lead to identification of predictive biomarkers and novel therapeutic targets, paving the way toward improving patient outcomes.Experimental designParental breast cancer cells and their endocrine-resistant derivatives (EndoR) were used. Derivatives with acquired resistance to palbociclib (PalboR) were generated from parental and estrogen deprivation-resistant MCF7 and T47D cells. Transcriptomic and proteomic analyses were performed in palbociclib-sensitive and PalboR lines. Gene expression data from CDK4/6i neoadjuvant trials and publicly available datasets were interrogated for correlations of gene signatures and patient outcomes.ResultsParental and EndoR breast cancer lines showed varying degrees of sensitivity to palbociclib. Transcriptomic analysis of these cell lines identified an association between high IFN signaling and reduced CDK4/6i sensitivity; thus an "IFN-related palbociclib-resistance Signature" (IRPS) was derived. In two neoadjuvant trials of CDK4/6i plus endocrine therapy, IRPS and other IFN-related signatures were highly enriched in patients with tumors exhibiting intrinsic resistance to CDK4/6i. PalboR derivatives displayed dramatic activation of IFN/STAT1 signaling compared with their short-term treated or untreated counterparts. In primary ER+/HER2- tumors, the IRPS score was significantly higher in lumB than lumA subtype and correlated with increased gene expression of immune checkpoints, endocrine resistance, and poor prognosis.ConclusionsAberrant IFN signaling is associated with intrinsic resistance to CDK4/6i. Experimentally, acquired resistance to palbociclib is associated with activation of the IFN pathway, warranting additional studies to clarify its involvement in resistance to CDK4/6i.

Published
2021

2. Sensitive tumor detection, accurate quantification, and cancer subtype classification using low-pass whole methylome sequencing of plasma DNA

Author

Paoli, Marta, primary, Galardi, Francesca, additional, Nardone, Agostina, additional, Biagioni, Chiara, additional, Romagnoli, Dario, additional, Di Donato, Samantha, additional, Franceschini, Gian Marco, additional, Livraghi, Luca, additional, Pestrin, Marta, additional, Sanna, Giuseppina, additional, Risi, Emanuela, additional, Migliaccio, Ilenia, additional, Moretti, Erica, additional, Malorni, Luca, additional, Biganzoli, Laura, additional, Demichelis, Francesca, additional, and Benelli, Matteo, additional

Published
2024
Full Text
View/download PDF

4. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial

Author

Migliaccio, Ilenia, primary, Romagnoli, Dario, additional, Galardi, Francesca, additional, De Luca, Francesca, additional, Biagioni, Chiara, additional, Curigliano, Giuseppe, additional, Criscitiello, Carmen, additional, Minisini, Alessandro Marco, additional, Moretti, Erica, additional, Risi, Emanuela, additional, Guarducci, Cristina, additional, Nardone, Agostina, additional, Biganzoli, Laura, additional, Benelli, Matteo, additional, and Malorni, Luca, additional

Published
2024
Full Text
View/download PDF

5. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, Giuliano, Mario, Migliaccio, Ilenia, Wang, Tao, Creighton, Chad J, Lupien, Mathieu, Fu, Xiaoyong, Hilsenbeck, Susan G, Healy, Nuala, De Angelis, Carmine, Mazumdar, Abhijit, Trivedi, Meghana V, Massarweh, Suleiman, Gutierrez, Carolina, De Placido, Sabino, Jeselsohn, Rinath, Brown, Myles, Brown, Powel H, Osborne, C Kent, and Schiff, Rachel

Subjects
Breast Cancer, Genetics, Cancer, Estrogen, Aetiology, 2.1 Biological and endogenous factors, Animals, Breast Neoplasms, Cell Proliferation, Drug Resistance, Neoplasm, Drug Synergism, Estradiol, Female, Humans, MCF-7 Cells, Mice, Promoter Regions, Genetic, Receptors, Estrogen, Tamoxifen, Transcription Factor AP-1, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis, Developmental Biology, Oncology & Carcinogenesis
Abstract

UnlabelledThe transcription factor AP-1 is downstream of growth factor (GF) receptors (GFRs) and stress-related kinases, both of which are implicated in breast cancer endocrine resistance. Previously, we have suggested that acquired endocrine resistance is associated with increased activity of AP-1 in an in vivo model. In this report, we provide direct evidence for the role of AP-1 in endocrine resistance. First, significant overlap was found between genes modulated in tamoxifen resistance and a gene signature associated with GF-induced estrogen receptor (ER) cistrome. Interestingly, these overlapping genes were enriched for key signaling components of GFRs and stress-related kinases and had AP-1 motifs in their promoters/enhancers. Second, to determine a more definitive role of AP-1 in endocrine resistance, AP-1 was inhibited using an inducible dominant-negative (DN) cJun expressed in MCF7 breast cancer cells in vitro and in vivo AP-1 blockade enhanced the antiproliferative effect of endocrine treatments in vitro, accelerated xenograft tumor response to tamoxifen and estrogen deprivation in vivo, promoted complete regression of tumors, and delayed the onset of tamoxifen resistance. Induction of DN-cJun after the development of tamoxifen resistance resulted in dramatic tumor shrinkage, accompanied by reduced proliferation and increased apoptosis. These data suggest that AP-1 is a key determinant of endocrine resistance by mediating a global shift in the ER transcriptional program.ImplicationsAP-1 represents a viable therapeutic target to overcome endocrine resistance. Mol Cancer Res; 14(5); 470-81. ©2016 AACR.

Published
2016

6. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, De Luca, Francesca, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Di Leo, Angelo, and Malorni, Luca

Published
2021
Full Text
View/download PDF

9. Targeting the CDK4/6 Pathway in Breast Cancer

Author

Malorni, Luca, Migliaccio, Ilenia, Guarducci, Cristina, Bonechi, Martina, Di Leo, Angelo, Veronesi, Umberto, editor, Goldhirsch, Aron, editor, Veronesi, Paolo, editor, Gentilini, Oreste Davide, editor, and Leonardi, Maria Cristina, editor

Published
2017
Full Text
View/download PDF

10. Supplementary table 3 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

11. Data from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

14. Supplementary table 4 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

15. Supplementary table 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

16. Supplementary table 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

17. Legend for supplementay figures from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Author

Malorni, Luca, primary, Giuliano, Mario, primary, Migliaccio, Ilenia, primary, Wang, Tao, primary, Creighton, Chad J., primary, Lupien, Mathieu, primary, Fu, Xiaoyong, primary, Hilsenbeck, Susan G., primary, Healy, Nuala, primary, De Angelis, Carmine, primary, Mazumdar, Abhijit, primary, Trivedi, Meghana V., primary, Massarweh, Suleiman, primary, Gutierrez, Carolina, primary, De Placido, Sabino, primary, Jeselsohn, Rinath, primary, Brown, Myles, primary, Brown, Powel H., primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figures from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, primary, Fu, Xiaoyong, primary, Cataldo, Maria Letizia, primary, Nardone, Agostina, primary, Pereira, Resel, primary, Veeraraghavan, Jamunarani, primary, Nanda, Sarmistha, primary, Qin, Lanfang, primary, Sethunath, Vidyalakshmi, primary, Wang, Tao, primary, Hilsenbeck, Susan G., primary, Benelli, Matteo, primary, Migliaccio, Ilenia, primary, Guarducci, Cristina, primary, Malorni, Luca, primary, Litchfield, Lacey M., primary, Liu, Jiangang, primary, Donaldson, Joshua, primary, Selenica, Pier, primary, Brown, David N., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Park, Ben H., primary, Hurvitz, Sara A., primary, Slamon, Dennis J., primary, Rimawi, Mothaffar F., primary, Jansen, Valerie M., primary, Jeselsohn, Rinath, primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

19. Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, primary, Fu, Xiaoyong, primary, Cataldo, Maria Letizia, primary, Nardone, Agostina, primary, Pereira, Resel, primary, Veeraraghavan, Jamunarani, primary, Nanda, Sarmistha, primary, Qin, Lanfang, primary, Sethunath, Vidyalakshmi, primary, Wang, Tao, primary, Hilsenbeck, Susan G., primary, Benelli, Matteo, primary, Migliaccio, Ilenia, primary, Guarducci, Cristina, primary, Malorni, Luca, primary, Litchfield, Lacey M., primary, Liu, Jiangang, primary, Donaldson, Joshua, primary, Selenica, Pier, primary, Brown, David N., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Park, Ben H., primary, Hurvitz, Sara A., primary, Slamon, Dennis J., primary, Rimawi, Mothaffar F., primary, Jansen, Valerie M., primary, Jeselsohn, Rinath, primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

20. Supplemental Figure 1 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer

Author

Jeselsohn, Rinath, primary, Barry, William T., primary, Migliaccio, Ilenia, primary, Biagioni, Chiara, primary, Zhao, Jin, primary, De Tribolet-Hardy, Jonas, primary, Guarducci, Cristina, primary, Bonechi, Martina, primary, Laing, Naomi, primary, Winer, Eric P., primary, Brown, Myles, primary, Leo, Angelo Di, primary, and Malorni, Luca, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, primary, Fu, Xiaoyong, primary, Cataldo, Maria Letizia, primary, Nardone, Agostina, primary, Pereira, Resel, primary, Veeraraghavan, Jamunarani, primary, Nanda, Sarmistha, primary, Qin, Lanfang, primary, Sethunath, Vidyalakshmi, primary, Wang, Tao, primary, Hilsenbeck, Susan G., primary, Benelli, Matteo, primary, Migliaccio, Ilenia, primary, Guarducci, Cristina, primary, Malorni, Luca, primary, Litchfield, Lacey M., primary, Liu, Jiangang, primary, Donaldson, Joshua, primary, Selenica, Pier, primary, Brown, David N., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Park, Ben H., primary, Hurvitz, Sara A., primary, Slamon, Dennis J., primary, Rimawi, Mothaffar F., primary, Jansen, Valerie M., primary, Jeselsohn, Rinath, primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Materials and Methods from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, primary, Fu, Xiaoyong, primary, Cataldo, Maria Letizia, primary, Nardone, Agostina, primary, Pereira, Resel, primary, Veeraraghavan, Jamunarani, primary, Nanda, Sarmistha, primary, Qin, Lanfang, primary, Sethunath, Vidyalakshmi, primary, Wang, Tao, primary, Hilsenbeck, Susan G., primary, Benelli, Matteo, primary, Migliaccio, Ilenia, primary, Guarducci, Cristina, primary, Malorni, Luca, primary, Litchfield, Lacey M., primary, Liu, Jiangang, primary, Donaldson, Joshua, primary, Selenica, Pier, primary, Brown, David N., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Park, Ben H., primary, Hurvitz, Sara A., primary, Slamon, Dennis J., primary, Rimawi, Mothaffar F., primary, Jansen, Valerie M., primary, Jeselsohn, Rinath, primary, Osborne, C. Kent, primary, and Schiff, Rachel, primary

Published
2023
Full Text
View/download PDF

23. Abstract P5-02-17: Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials

Author

Malorni, Luca, primary, Benelli, Matteo, additional, Liu, Yuan, additional, Deng, Shibing, additional, Zhang, Zhe, additional, Guarducci, Cristina, additional, Leo, Angela, additional, Nardone, Agostina, additional, Galardi, Francesca, additional, Risi, Emanuela, additional, Moretti, Erica, additional, Romagnoli, Dario, additional, Biagioni, Chiara, additional, Paoli, Marta, additional, Biganzoli, Laura, additional, and Migliaccio, Ilenia, additional

Published
2023
Full Text
View/download PDF

24. Abstract P3-05-45: Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy

Author

Risi, Emanuela, primary, Pestrin, Marta, additional, Biagioni, Chiara, additional, Romagnoli, Dario, additional, Migliaccio, Ilenia, additional, Galardi, Francesca, additional, De Luca, Francesca, additional, Benelli, Matteo, additional, Moretti, Erica, additional, Sanna, Giuseppina, additional, Livraghi, Luca, additional, Cappadona, Silvia, additional, Marsico, Roberta Di, additional, Amoroso, Domenico, additional, Martignetti, Angelo, additional, Ribecco, Angela S., additional, Caremoli, Elena Rota, additional, Coltelli, Luigi, additional, Puglisi, Fabio, additional, Malorni, Luca, additional, and Biganzoli, Laura, additional

Published
2023
Full Text
View/download PDF

25. Abstract P5-02-27: Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial

Author

McCartney, Amelia, primary, Biagioni, Chiara, additional, Chen, Bingshu, additional, Shepherd, Lois, additional, Gelmon, Karen, additional, Joy, Anil A., additional, Parulekar, Wendy, additional, Bergqvist, Mattias, additional, Migliaccio, Ilenia, additional, Leo, Angela, additional, Benelli, Matteo, additional, Risi, Emanuela, additional, Moretti, Erica, additional, Livraghi, Luca, additional, Biganzoli, Laura, additional, and Malorni, Luca, additional

Published
2023
Full Text
View/download PDF

26. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Author

Rossi, Lorenzo, Biagioni, Chiara, McCartney, Amelia, Migliaccio, Ilenia, Curigliano, Giuseppe, Sanna, Giuseppina, Moretti, Erica, Minisini, Alessandro M., Cinieri, Saverio, Tondini, Carlo, Arpino, Grazia, Bernardo, Antonio, Martignetti, Angelo, Risi, Emanuela, Pestrin, Marta, Boni, Luca, Benelli, Matteo, Biganzoli, Laura, Di Leo, Angelo, and Malorni, Luca

Published
2019
Full Text
View/download PDF

27. MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples

Author

Romagnoli, Dario, primary, Nardone, Agostina, additional, Galardi, Francesca, additional, Paoli, Marta, additional, De Luca, Francesca, additional, Biagioni, Chiara, additional, Franceschini, Gian Marco, additional, Pestrin, Marta, additional, Sanna, Giuseppina, additional, Moretti, Erica, additional, Demichelis, Francesca, additional, Migliaccio, Ilenia, additional, Biganzoli, Laura, additional, Malorni, Luca, additional, and Benelli, Matteo, additional

Published
2023
Full Text
View/download PDF

31. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Author

UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Malorni, Luca, Tyekucheva, Svitlana, Hilbers, Florentine S, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, HENRY, Stéphanie, Ballestrero, Alberto, Bonetti, Andrea, Jerusalem, Guy, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, Francois, MacPherson, Iain R, Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Migliaccio, Ilenia, Gebhart, Géraldine, Zoppoli, Gabriele, Bliss, Judith M, Benelli, Matteo, McCartney, Amelia, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Fumagalli, Debora, Maibach, Rudolf, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith M, International Breast Cancer Study Group, Breast International Group and PYTHIA Collaborators, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Malorni, Luca, Tyekucheva, Svitlana, Hilbers, Florentine S, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, HENRY, Stéphanie, Ballestrero, Alberto, Bonetti, Andrea, Jerusalem, Guy, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, Francois, MacPherson, Iain R, Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Migliaccio, Ilenia, Gebhart, Géraldine, Zoppoli, Gabriele, Bliss, Judith M, Benelli, Matteo, McCartney, Amelia, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Fumagalli, Debora, Maibach, Rudolf, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith M, International Breast Cancer Study Group, and Breast International Group and PYTHIA Collaborators

Abstract

Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively investigated the prognostic role of serum thymidine kinase activity (sTKa), in patients treated with Palbociclib + fulvestrant. PYTHIA was a phase II, single-arm, multicentre, trial that enrolled 124 post-menopausal women with endocrine-resistant hormone receptor-positive/HER2-negative metastatic breast cancer. Serum samples were collected pre-treatment (pre-trt; n = 122), at day 15 of cycle 1 (D15; n = 108), during the one week-off palbociclib before initiating cycle 2 (D28; n = 108) and at end of treatment (n = 76). sTKa was determined centrally using Divitum®, a refined ELISA-based assay with a limit of detection of 20 Divitum Units (Du)/L. The primary study endpoint was progression-free survival, assessed for its association with pre- and on-treatment sTKa. Data from 122 women were analysed. Pre-treatment sTKa was not associated with clinical characteristics and moderately correlated with tissue Ki-67. Palbociclib + fulvestrant markedly suppressed sTKa levels at D15, with 83% of patients recording levels below limit of detection. At D28, sTKa showed a rebound in 60% of patients. At each timepoint, higher sTKa was associated with shorter progression-free survival (each p < 0.001), with the strongest effect at D15. STKa is an independent prognostic biomarker in patients treated with palbociclib. High pre-treatment sTKa and its incomplete suppression during treatment may identify patients with poorer prognosis and primary resistance. This warrants validation in prospective comparative trials. CLINICALTRIALS. NCT02536742; EudraCT 2014-005387-15.

Published
2022

32. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Author

Malorni, Luca, primary, Tyekucheva, Svitlana, additional, Hilbers, Florentine S., additional, Ignatiadis, Michail, additional, Neven, Patrick, additional, Colleoni, Marco, additional, Henry, Stéphanie, additional, Ballestrero, Alberto, additional, Bonetti, Andrea, additional, Jerusalem, Guy, additional, Papadimitriou, Konstantinos, additional, Bernardo, Antonio, additional, Seles, Elena, additional, Duhoux, Francois P., additional, MacPherson, Iain R., additional, Thomson, Alastair, additional, Davies, David Mark, additional, Bergqvist, Mattias, additional, Migliaccio, Ilenia, additional, Gebhart, Géraldine, additional, Zoppoli, Gabriele, additional, Bliss, Judith M., additional, Benelli, Matteo, additional, McCartney, Amelia, additional, Kammler, Roswitha, additional, De Swert, Heidi, additional, Ruepp, Barbara, additional, Fumagalli, Debora, additional, Maibach, Rudolf, additional, Cameron, David, additional, Loi, Sherene, additional, Piccart, Martine, additional, and Regan, Meredith M., additional

Published
2022
Full Text
View/download PDF

34. Abstract P3-05-02: A minimal DNA-methylation signature to estimate tumor content and molecular subtype in breast cancer tissue samples with potential application to liquid biopsy

Author

Romagnoli, Dario, primary, Galardi, Francesca, additional, De Luca, Francesca, additional, Biagioni, Chiara, additional, Moretti, Erica, additional, Biganzoli, Laura, additional, Migliaccio, Ilenia, additional, Malorni, Luca, additional, and Benelli, Matteo, additional

Published
2022
Full Text
View/download PDF

35. Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse

Author

Vignoli, Alessia, primary, Mori, Elena, additional, Di Donato, Samantha, additional, Malorni, Luca, additional, Biagioni, Chiara, additional, Benelli, Matteo, additional, Calamai, Vanessa, additional, Cantafio, Stefano, additional, Parnofiello, Annamaria, additional, Baraghini, Maddalena, additional, Garzi, Alessia, additional, Monte, Francesca Del, additional, Romagnoli, Dario, additional, Migliaccio, Ilenia, additional, Luchinat, Claudio, additional, Tenori, Leonardo, additional, and Biganzoli, Laura, additional

Published
2021
Full Text
View/download PDF

36. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Author

De Angelis, Carmine, primary, Fu, Xiaoyong, additional, Cataldo, Maria Letizia, additional, Nardone, Agostina, additional, Pereira, Resel, additional, Veeraraghavan, Jamunarani, additional, Nanda, Sarmistha, additional, Qin, Lanfang, additional, Sethunath, Vidyalakshmi, additional, Wang, Tao, additional, Hilsenbeck, Susan G., additional, Benelli, Matteo, additional, Migliaccio, Ilenia, additional, Guarducci, Cristina, additional, Malorni, Luca, additional, Litchfield, Lacey M., additional, Liu, Jiangang, additional, Donaldson, Joshua, additional, Selenica, Pier, additional, Brown, David N., additional, Weigelt, Britta, additional, Reis-Filho, Jorge S., additional, Park, Ben H., additional, Hurvitz, Sara A., additional, Slamon, Dennis J., additional, Rimawi, Mothaffar F., additional, Jansen, Valerie M., additional, Jeselsohn, Rinath, additional, Osborne, C. Kent, additional, and Schiff, Rachel, additional

Published
2021
Full Text
View/download PDF

39. A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting

Author

Di Donato, Samantha, primary, Vignoli, Alessia, additional, Biagioni, Chiara, additional, Malorni, Luca, additional, Mori, Elena, additional, Tenori, Leonardo, additional, Calamai, Vanessa, additional, Parnofiello, Annamaria, additional, Di Pierro, Giulia, additional, Migliaccio, Ilenia, additional, Cantafio, Stefano, additional, Baraghini, Maddalena, additional, Mottino, Giuseppe, additional, Becheri, Dimitri, additional, Del Monte, Francesca, additional, Miceli, Elisangela, additional, McCartney, Amelia, additional, Di Leo, Angelo, additional, Luchinat, Claudio, additional, and Biganzoli, Laura, additional

Published
2021
Full Text
View/download PDF

41. Additional file 5 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Abstract

Additional file 5: Figure S5. RB1 and GAPDH gene expression analysis. A) distribution of GAPDH and RB1 copies number in single CTCs, B) distribution of mean number of copies of GAPDH and RB1 (tot n copies/n cells).

Published
2021
Full Text
View/download PDF

42. Additional file 6 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Abstract

Additional file 6: Figure S6. Mean number of copies of GAPDH and RB1 broken into timepoint.

Published
2021
Full Text
View/download PDF

43. Additional file 3 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Subjects
food and beverages, eye diseases
Abstract

Additional file 3: Figure S3. Cell lines set up of ddPCR assay. A) RB1 expression on PDS and PDR cell lines confirm the reduction of RB1 expression among PDS and PDS cell lines, *** p

Published
2021
Full Text
View/download PDF

44. Additional file 1 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Abstract

Additional file 1: Figure S1. CTCs dynamics. Spider plot of CTC dynamics for each timepoint colored according to CB.

Published
2021
Full Text
View/download PDF

45. Additional file 2 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Abstract

Additional file 2: Figure S2. T47D set up of ddPCR assay. A, B-2D plot of T47D PDS and PDR, C, D- concentration plot of T47D PDS and PDR; PDS: sensitive to palbociclib, PDR resistant to palbociclib.

Published
2021
Full Text
View/download PDF

46. Additional file 4 of Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Author

Galardi, Francesca, Luca, Francesca De, Biagioni, Chiara, Migliaccio, Ilenia, Curigliano, Giuseppe, Minisini, Alessandro M., Bonechi, Martina, Moretti, Erica, Risi, Emanuela, McCartney, Amelia, Benelli, Matteo, Romagnoli, Dario, Cappadona, Silvia, Gabellini, Stefano, Guarducci, Cristina, Conti, Valerio, Biganzoli, Laura, Leo, Angelo Di, and Malorni, Luca

Abstract

Additional file 4: Figure S4. Images of a patient sample CTCs. Images of CTCs identified by A) Cell Search system, B) DEP array. C) 2-D plot RB1- droplets positive for Rb1 expression, GAPDH- droplets positive for GAPDH; RB1+ GAPDH- droplets positive for both RB1 and GAPDH.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results